Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Shares of Biogen Inc. BIIB slid 5.91% to $122.98 Friday, on what proved to be an all-around rough trading session for the ...

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

As previously reported, Argus downgraded Biogen (BIIB) to Hold from Buy. The company has provided guidance for 2025, noting that it expects ...

Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy.Don't Miss Our End of Quarter Offers: Discover the latest stocks ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

(Alliance News) - BioPharma Credit PLC on Wednesday said it has received a USD8.3 million settlement payment from Biogen Inc as the final resolution of a loan dispute.

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...